DETAILS, FICTION AND LDN-27219 DRUG DEVELOPMENT PIPELINE

A single specifically fascinating compound is LDN-27219. While most tTG inhibitors are designed to bind on the protein crosslinking active web page, LDN-27219 in its place binds on the nucleotide binding pocket in the enzyme though it can be in its closed-condition conformation, and stabilizes that conformation to circumvent crosslinking activity.7